My investment philosophy focuses on compounding capital at 12-15% annually, prioritizing high-quality, blue-chip companies with wide moats and strong balance sheets. I emphasize concentrated ...
Procter & Gamble (NYSE: PG) confirmed a bottom in early 2026, with its stock price set to advance significantly over the ...
Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...